Report Overview

The UK Fragile X Syndrome Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Fragile X Syndrome (FXS), also termed Martin-Bell syndrome or marker X syndrome, is the most common cause of inherited mental retardation, intellectual disability, and autism and is the second most common cause of genetically associated mental deficiencies, after trisomy 21.

Fragile X syndrome is characterized by moderate intellectual disability in affected males and mild intellectual disability in affected females. Distinctive physical features are sometimes present in affected males including a large head, long face, prominent forehead and chin, protruding ears, loose joints, and large testes, but these features develop over time and may not be obvious until puberty. Behavioral abnormalities including autistic behaviors are common.

Fragile X syndrome is one of the most common forms of inherited learning disability; it may also cause associated physical conditions. Prevalence estimates from a UK screening study estimated an overall prevalence of 1 in 4,000 boys and 1 in 8000 girls. As the gene for the fragile X is located on the X chromosome the prevalence is less in females. Men are more often affected by this disorder than women. About 15% of men and 5% of women suffering from fragile X syndrome can experience seizures. The criterion standard diagnostic test for fragile X syndrome involves molecular genetic techniques that detect the FMR1 gene.



Market Growth Drivers

However, the presence of a strong pipeline that increases the focus of pharmaceuticals & biotechnology companies on conducting research programs for the effective treatment of syndrome also boosts up the market growth.

Moreover, rising cases of genetic mutation syndromes and increases in unhealthy lifestyles (such as smoking cigarettes, alcohol drinking, and others) by women during pregnancy also boost up the market growth.

High investment in research & development by leading industry participants is expected to open a new growth window for them. With strong research and development initiative, most of the companies are focusing on innovative and cost-effective drug development

Huge financial support to the researchers for developing novel interventions is boosting the market growth. The high demand for disease-specific novel treatment can also act as a market driver.

Market Restraints

However, the high cost of treatment and the lack of awareness for Fragile X Syndrome acts as a major restraint and as well as may hamper the market growth over the forecast period.